Please login to the form below

Not currently logged in
Email:
Password:

Astellas boosts US antibody centre with new hires

Wolfgang Noe and Frank Hudson join pharma company's Santa Monica affiliate Agensys

Astellas has appointed Wolfgang Noe and Frank Hudson to its US antibody research affiliate Agensys.

Noe joins as vice president of process sciences and manufacturing and comes to the Santa Monica-based company from Biogen Idec, where he spent seven years, most recently as vice president of strategic development and technical alliances.

Prior to Biogen Noe began his pharma career with Boehringer-Ingelheim Pharmaceuticals in Germany.

In his new role at Agensys he will be responsible for manufacturing development and manufacturing of clinical and preclinical drug supplies.

Meanwhile, Agensys has appointed Frank Hudson as vice president of finance.

He has more than 20 years of pharmaceutical experience and moves to Agensys from the Mannkind Corporation where he served as vice president of finance since 2007.

At Agensys, Hudson will be responsible for finance, procurement and information technology.

"Frank and Wolfgang each bring a wealth of experience from the biopharma industry to their respective positions," said Sef Kurstjens, president and CEO of Agensys. "Frank's experience in research and development finance is exactly what we were looking for in our candidates, and Wolfgang's record in preclinical and clinical drug development brings additional strength to our operations."

Agensys, which was acquired by Astellas in 2007, focuses on antibody product discovery and development, and plans to finish work on a new research and development facility in 2013.

2nd December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics